This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignees: Beijing Neocurna Biotechnology Corporation, Neocura Bio-Medical Technology Co., Ltd, Shenzhen Neocurna Biotechnology Corporation. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 1 Years Active: 2024
Title: The Innovative Contributions of An Xiao in Immunogenicity Detection
Introduction
An Xiao is an inventor based in Shenzhen, China, recognized for his innovative contributions in the biomedical field. His work focuses on the detection of immunogenicity related to tumor neoantigens, an area of great significance in cancer research and treatment.
Latest Patents
An Xiao holds a patent for a "Method and platform for detecting immunogenicity of tumor neoantigen." This invention presents an effective approach for identifying the immunogenic properties of tumor neoantigens. The method involves culturing human peripheral blood monocytes ex vivo for 13 days, introducing antigenic peptide fragments of human influenza virus, and engaging cytokines, antigenic peptides, and immunoadjuvants throughout the culture period. The process culminates in an enzyme-linked immunospot (ELISPOT) chromogenic reaction, leading to precise detection and analysis of immunogenicity. Compared to prior methodologies, this innovation boasts a shorter detection timeframe, greater convenience, lower consumption of experimental cells, and reduced costs, making it suitable for high-throughput assays in biomedicine.
Career Highlights
Throughout his career, An Xiao has been affiliated with prominent companies such as Neocura Biomedical Technology Co., Ltd. and Beijing Neocurna Biotechnology Corporation. His experience in these organizations has solidified his expertise in the biomedical sector, further enhancing his innovative research contributions.
Collaborations
An Xiao has collaborated with notable professionals in his field, including Youdong Pan and Qi Song. These partnerships have fostered a collaborative environment, enabling the exchange of ideas and the advancement of shared goals in tumor immunogenicity research.
Conclusion
An Xiao's innovations have significantly contributed to the biomedical landscape, particularly in detecting tumor neoantigen immunogenicity. His patented method exemplifies the potential of innovative solutions to enhance cancer research and patient outcomes. The collaborative efforts with industry peers further emphasize the importance of teamwork in advancing scientific discoveries and applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile